Skip to content

A Comparative Study on the Effectiveness of Electroconvulsive Therapy and Ketamine in Persons Suffering from Treatment-resistant Depressive Disorder

V. Ramasubramanian, S. Mathumathi, G. Thirumalaisamy, Sugaparaneetharan Ayyanar, Gopi Rajendhiran, M. Kannan

Indian Journal of Psychiatric Nursing July 1, 2024 DOI: 10.4103/iopn.iopn_93_23 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Prospective, parallel randomized controlled, open label, noninferiority/superiority trial Open-label Peer reviewed
Sample size 96
Population People with treatment-resistant depression
Interventions Ketamine Electroconvulsive therapy (ECT)
Dose six doses of ketamine; 6 ECT treatments
Measures Hamilton depression ratings scale (HAM-D)
Topics Depression Esketamine Ketamine
Key findings Ketamine produced an antidepressant effect comparable to ECT in people with treatment-resistant depression, and the authors report that it reduced depressive symptoms more rapidly than ECT. They conclude that ketamine can be considered an effective alternative to ECT in this population.

Abstract

ABSTRACT Depression is a common illness that affects about 3.8% of the population worldwide. Patients with major depression respond to antidepressant treatment, but 10%–20% of them do not improve or show a partial response. It is coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. Treatment-resistant depression (TRD) is a challenge to clinicians because of its increased loss of functionality and the increased rate of suicide among people diagnosed with the illness. Studies are evolving to combine various treatment options to reduce morbidity and mortality in people suffering from the illness. This study aims at comparing the efficacy of electroconvulsive therapy (ECT) and ketamine transfusion in treating TRD. It hopes to prove that ketamine provides rapid relief for people suffering from TRD. A prospective, parallel randomized controlled, open label, noninferiority/superiority trial to compare the efficacy of ECT and ketamine was done. Ninety-six persons suffering from TRD were selected for the study through proportionate stratified random sampling and 46 persons received 6 ECT treatment and 50 persons received six doses of ketamine. Treatment response was measured using Hamilton depression ratings scale (HAM-D) using baseline, mid assessment, and postassessment scores. The scores were used to determine the effectiveness of ECT and ketamine in the treatment of TRD. Ketamine was proven to have the same antidepressant effect in participants as that of ECT. Ketamine was observed to have rapid reduction in depressive symptoms when compared to ECT. This study highlights that ketamine can be considered as an effective alternative to ECT in those with TRD.

Comparable studies

Other randomized controlled trials on ketamine for depression, most cited first.

Study Year Design Participants
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial Patients with treatment-resistant major depression experiencing a major depressive episode 2013 Randomized controlled trial n = 73
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Adults with moderate to severe nonpsychotic depression and a history of nonresponse to... 2019 Phase 3, double-blind, active-controlled, multicenter randomized controlled trial n = 227
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression Adults with treatment-resistant depression who achieved stable remission or stable... 2019 Phase 3, multicenter, double-blind, randomized withdrawal study n = 297
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression Adults with DSM-IV-TR diagnosis of major depressive disorder and history of inadequate... 2017 Phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study n = 67
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Depressed patients at imminent risk for suicide 2018 Randomized controlled trial n = 68

Explore topics

By condition and practice